Antihypertensive Effects of Rosmarinus Officinalis L. Infusion

Antihypertensive Effects of Rosmarinus Officinalis L. Infusion Supplements in Male Patients With Mild Hypertension : A Randomized Double-Blind Placebo-Controlled Study

This study assessed the antihypertensive effect of rosemary tea through a placebo-controlled clinical study, angiotensin-converting enzyme (ACE) inhibition analysis, and in silico evaluation of interactions between rosemary bioactive compounds and the AT1R (Angiotensin II Type 1 Receptor).

A randomized, double-blind, placebo-controlled trial was conducted in 54 male patients with mild hypertension. Participants were assigned to receive either rosemary infusion (n = 27) or placebo (n = 23) for 45 days. Ambulatory blood pressure monitoring wass used to evaluate blood pressure parameters. Serum ACE activity was measured at baseline and after the intervention using FAPGG hydrolysis. Molecular docking simulations were performed using the Dock 4.2 software.

Inclusion Criteria:

• Male participants aged 28-65 years
• Mild hypertension, defined as systolic blood pressure (SBP) 140-159 mmHg and/or diastolic blood pressure (DBP) 90-99 mmHg, according to ESC/ESH 2018 guidelines
• No history of chronic diseases
• Not currently taking antihypertensive medications, other drugs, or dietary supplements
• Body mass index (BMI) within the screening range at recruitment
• Provided written informed consent

Exclusion Criteria:

• Secondary hypertension
• History of cardiovascular disease, diabetes mellitus, renal failure, autoimmune disease, or major gastrointestinal disorders
• Current use of medications affecting blood pressure
• Extreme body mass index (BMI) values
• Significant dietary changes or irregular physical activity in the previous six months
• Alcohol consumption or use of illicit drugs
• Inability or unwillingness to maintain usual diet and lifestyle during the study